Povetacicept

Protein / enzyme therapeutic

Filedunder review

Evidence outlook · regulatory review

IgA Nephropathy: application under FDA review, decision date 2026-11-30

FDA accepts povetacicept BLA for accelerated approval in IgAN (2026-06-01). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Also in development:Primary Membranous Nephropathy · Phase 2/3Myasthenia Gravis · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
IgA Nephropathy
NCT07807995 · Vertex Pharmaceuticals Incorporated
2026-09-17 – 2029-12-28 · Immunoglobulin A Nephropathy
What this study did
NCT07890909 · Vertex Pharmaceuticals Incorporated
2026-11-13 – 2028-03-02 · Immunoglobulin A Nephropathy
What this study did
Phase 2/3 (1)
Primary Membranous Nephropathy
Phase 2 (1)
Myasthenia Gravis
Phase 1/2 (2)
IgA Nephropathy
NCT05732402 · Alpine Immune Sciences, Inc.
2023-03-15 – 2028-03-02 · Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
What this study did
Other / comorbidity
NCT05757570 · Alpine Immune Sciences Inc, A Subsidiary of Vertex
2023-07-03 – 2026-08-12 · Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
What this study did
Phase 1 (2)
Other / comorbidity
NCT07010406 · Vertex Pharmaceuticals Incorporated
2025-06-06 – 2025-08-19 · Healthy Volunteers
What this study did
NCT05034484 · Alpine Immune Sciences, Inc.
2021-11-15 – 2023-02-27 · Healthy Volunteers
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for IgA Nephropathy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Povetacicept: this drugPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
AtaciceptApprovedProtein / enzyme therapeuticBLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand)Partial signalFeatured results are non-efficacy only in this race
Atrasentan (Vanrafia)ApprovedSmall moleculeEndothelin A receptorPartial signal
NCT04573478: Primary (interim, first 270 patients): 24-hour UPCR change at week 36, atrasentan -38.1% vs placebo -3.1%; between-group difference -36.1 percentage points (95% CI -44.6 to -26.4), P<0.001
Budesonide (targeted-Release) (TARPEYO / Nefecon)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT06291376: Primary 1, change in 24-hour UPCR at week 34 (prespecified interim analysis), ravulizumab vs placebo: the sponsor reports a statistically significant and clinically meaningful reduction, met; figures not yet published. Primary 2, change in eGFR at week 106: not yet reported; the trial is ongoing.
Sparsentan (Filspari)ApprovedSmall moleculeAngiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Partial signalFeatured results are non-efficacy only in this race
FelzartamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
JADE101Phase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SefaxersenPhase 3RNA / oligonucleotideComplement factor B (CFB)Partial signal
NCT05797610: Prespecified interim analysis: statistically significant reduction in proteinuria (24-hour UPCR) vs placebo at week 37 (2026-09-23).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
Aritinercept
Phase 1/2(overall)
Protein / enzyme therapeuticBAFF / APRIL
not yet graded(overall)
No reviewed efficacy summary in this indication
SCTC21CPhase 1/2Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
ARO-CFBPhase 1RNA / oligonucleotideComplement factor B (CFB) mRNAnot yet gradedNo reviewed efficacy summary in this indication
Opemalirsen
Phase 1(overall)
RNA / oligonucleotide—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Povetacicept to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 3IgA NephropathyRecruiting
Est. primary completion 2027-12-12 · NCT07890909 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Phase 3IgA NephropathyActive not recruiting
Est. primary completion 2028-01-30 · NCT06564142 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1/2IgA NephropathyActive not recruiting
Est. primary completion 2028-03-02 · NCT05732402 · CT.gov ↗
What to watch
2029 (3)
March 2029 (1)
Phase 2Myasthenia GravisActive not recruiting
Est. primary completion 2029-03-02 · NCT07501702 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2/3Primary Membranous NephropathyRecruiting
Est. primary completion 2029-06-27 · NCT07204275 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3IgA NephropathyEnrolling by invitation
Est. primary completion 2029-12-28 · NCT07807995 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

30 November 2026FDA action datePDUFA date 30 November 2026 for povetacicept in IgAN
US, FDA · Vertex Pharmaceuticals · Source ↗

Recent

1 June 2026Filing acceptedFDA accepts povetacicept BLA for accelerated approval in IgAN
US, FDA · Vertex Pharmaceuticals · Source ↗